Takeda Pharmaceutical Co LtdTAK
What Takeda Pharmaceutical Co Ltd does.
We are a global R&D-driven biopharmaceutical company focused on discovering and delivering life-transforming treatments in our core therapeutic areas of gastrointestinal and inflammation, neuroscience and oncology, as well as through our plasma-derived therapies and vaccines business. Our intent is to translate science into highly innovative life-transforming medicines. We have built an R&D engine focused on three core therapeutic areas, leveraging internal research and external partners in order to have access to different modalities like biologics or small molecules. We have a geographically diversified global business base and our prescription drugs are marketed worldwide.
We have approximatel y 47,000 employees worldwide, and our culture is based on our values of Takeda-ism which incorporates Integrity, Fairness, Honesty, and Perseverance, with Integrity at the core.
Our commercial efforts are focused on six key business areas of GI, Rare Diseases, PDT, Oncology, Vaccines and Neuroscience, which in the fiscal year ended March 31, 2026 accounted for 95.0% of our total revenue. We believe these business areas will drive our future revenue growth, and we will continue to make the necessary investments, as well as targ eted acquisitions and divestitures, to further sharpen our focus and maximize the contributions of our portfolios in these areas. As of March 31, 2026, the following Growth & Launch Products have been our growth driver products in our key business areas: ENTYVIO , EOHILIA, TAKHZYRO , LIVTENCITY , ADZYNMA , Immunoglobulin products (including GAMMAGARD LIQUID/KIOVIG, HYQVIA and CUVITRU), Albumin products (including HUMAN ALBUMIN/FLEXBUMIN ), FRUZAQLA, ALUNBRIG and QDENGA.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $3.29T | $3.20T | $3.57T | $4.03T | $4.26T | $4.58T |
| Net income | $44.2B | $376.0B | $230.1B | $317.0B | $144.1B | $107.9B |
| Free cash flow | $542.7B | $899.7B | $999.9B | $836.5B | $540.9B | $856.4B |
More on TAK.
- Takeda Pharmaceutical Co Ltd summary
- Takeda Pharmaceutical Co Ltd financial statements
- Takeda Pharmaceutical Co Ltd key metrics
- Takeda Pharmaceutical Co Ltd health scores and style box
- Takeda Pharmaceutical Co Ltd earnings
- Takeda Pharmaceutical Co Ltd dividends
- Takeda Pharmaceutical Co Ltd valuation
- Takeda Pharmaceutical Co Ltd ownership and insiders
- Takeda Pharmaceutical Co Ltd peers
Figures from Takeda Pharmaceutical Co Ltd's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.